Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Exelixis revenue
Exelixis's revenue is $2.2 billion.
What is Exelixis's revenue?
- Exelixis's revenue growth from 2002 to 2024 is 4,793.06%.
- Exelixis has 484 employees, and the revenue per employee ratio is $4,480,787.
- Exelixis's peak quarterly revenue was $637.2M in 2024(q2).
- Exelixis peak revenue was $2.2B in 2024.
- Exelixis annual revenue for 2023 was 1.8B, 13.6% growth from 2022.
- Exelixis annual revenue for 2024 was 2.2B, 18.49% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Exelixis historical revenue
Exelixis's peak revenue was $2.2B in 2024. The peak quarterly revenue was $637.2M in 2024(q2).
Exelixis's revenue increased from $44.3m in 2002 to $2.2B currently. That's a 4,793.06% change in annual revenue.
Exelixis annual revenue
Exelixis annual revenue over time
| Fiscal year / year | Exelixis revenue |
|---|---|
| 2009 | $151.8M |
| 2010 | $185.0M |
| 2011 | $289.6M |
| 2012 | $47.5M |
| 2013 | $47.5M |
| 2014 | $25.1M |
| 2015 | $37.2M |
| 2016 | $191.5M |
| 2017 | $452.5M |
| 2018 | $853.8M |
| 2019 | $967.8M |
| 2020 | $987.5M |
| 2021 | $1.4B |
| 2022 | $1.6B |
| 2023 | $1.8B |
| 2024 | $2.2B |
How accurately did Exelixis' revenue projections match actual performance?
Exelixis annual growth
Exelixis saw the greatest revenue growth in 2016, when revenue increased by 415.05%.
Exelixis had the lowest revenue growth in 2012, when revenue changed by -83.62%.
Exelixis annual growth rate over time
| Year | Exelixis growth |
|---|---|
| 2009 | 29%↑ |
| 2010 | 22%↑ |
| 2011 | 57%↑ |
| 2012 | -84%↓ |
| 2013 | 0%↓ |
| 2014 | -47%↓ |
| 2015 | 48%↑ |
| 2016 | 415%↑ |
| 2017 | 136%↑ |
| 2018 | 89%↑ |
| 2019 | 13%↑ |
| 2020 | 2%↑ |
| 2021 | 45%↑ |
| 2022 | 12%↑ |
| 2023 | 14%↑ |
| 2024 | 18%↑ |
Exelixis quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Exelixis quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | - | - | ($1.9M) |
| 2015 | $9.4M | $8.0M | $9.9M | $9.9M |
| 2016 | $15.4M | $36.3M | $62.2M | $77.6M |
| 2017 | $80.9M | $99.0M | $152.5M | $120.1M |
| 2018 | $212.3M | $186.1M | $225.4M | $228.6M |
| 2019 | $215.5M | $240.3M | $271.7M | $240.3M |
| 2020 | $226.9M | $259.5M | $231.1M | $270.1M |
| 2021 | $270.2M | $385.2M | $328.4M | $451.1M |
| 2022 | $356.0M | $419.4M | $411.7M | $423.9M |
| 2023 | $408.8M | $469.8M | $471.9M | $479.7M |
| 2024 | $425.2M | $637.2M | $539.5M | $566.8M |
Exelixis jobs nearby
Do you work at Exelixis?
Did Exelixis meet its revenue projections?
Exelixis financial information
| CEO | Michael M. Morrissey Ph.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 484 |
| Date Founded | 1994 |
| Headquarters | Alameda, California |
| Number of Locations | 1 |
| Revenue | $2.2B |
| Net Income | $182,282,000 |
| Gross Proft | $2.1B (2024) |
| EBITDA | ($90.7M) (2003) |
| PE Ratio | 10.50 |
| Tax Rate | 0.2% |
| Market Capitalization | $5.5B |
| Total Assets | $3,071,489,000 |
| Ticker | EXEL |
Exelixis jobs you might like
Exelixis financing
Exelixis received early financing of $4.0M on 1999-07-13.
| Series | Round size | Date |
|---|---|---|
| Seed | $4M | 07/1999 |
| Post Ipo Debt | $150M | 06/2008 |
| Post Ipo Debt | $160M | 06/2010 |
| Post Ipo Equity | $65M | 02/2012 |
Exelixis investors
| Investors | Security type |
|---|---|
| PaineWebber | Seed |
| Oxford Bioscience Partners | Seed |
| Atlas Venture | Seed |
| Deerfield Management | Post Ipo Debt |
| Deerfield Management | Post Ipo Debt |
| Silicon Valley Bank | Post Ipo Debt |
Exelixis competitors
Exelixis's top competitor, Merck, earned an annual revenue of $64.2B.
Exelixis's smallest competitor is GENEWIZ with revenue of $45.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 601 |
| Regeneron | $85,589 | $14.2B | 9,123 | 359 |
| Merck | $90,328 | $64.2B | 74,000 | 1,474 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 203 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 24 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Acadia Pharmaceuticals | $90,533 | $957.8M | 570 | 58 |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Zoetis | $87,092 | $9.3B | 11,300 | 225 |
| Intarcia Therapeutics | $76,606 | $70.0M | 44 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Exelixis highest paying jobs
Zippia gives an in-depth look into the details of Exelixis, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Exelixis. The employee data is based on information from people who have self-reported their past or current employments at Exelixis. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Exelixis. The data presented on this page does not represent the view of Exelixis and its employees or that of Zippia.
Exelixis may also be known as or be related to EXELIXIS INC, Exelixis, Exelixis Inc, Exelixis Pharmaceuticals, Inc. (1994-2000) and Exelixis, Inc.